Drug Trial Radar · NCT06966804
Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 1, 2025
Primary completion
May 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Penang Hospital, MalaysiaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare how well Terazosin, Tamsulosin and standard care (no alpha-blocker) reduce urinary symptoms after ureteral stent placement. This trial also learn about the safety of these two study medications. Main objective: • To compare how well Terazosin, Tamsulosin and standard of care reduce post-stenting urinary symptoms. Secondary objectives: * To assess differences in Body pain, General health, Work performance, Sexual matters, and Additional problems using a questionnaire (USSQ). * To assess differences in side effects. After stent placement, subjects will be randomly assigned to one of three groups: 1. Terazosin (alpha-blocker) for 14 days 2. Tamsulosin (alpha-blocker) for 14 days 3. Standard of care (no alpha-blocker). All subjects will be discharged with standard pain-killers and a diary to track usage. Subjects in Terazosin and Tamsulosin groups will receive respective study medications to complete 14 days course of treatment. Follow-Up: * Day 7: A phone call will check medication use and any side effects. * Day 15: Clinic visit for stent removal (standard practice). Subjects will complete the USSQ questionnaire, and medication compliance will be reviewed. End of study: Final phone call to check for any additional side effects.
Conditions
- Stent Related Symptoms
Interventions
TerazosinDrug
Subject will complete 14-day course of Terazosin
TamsulosinDrug
Subject will complete 14-day course of Tamsulosin
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the efficacy of Terazosin, Tamsulosin and standard of care in reducing post-stenting urinary symptomsTime frame: From randomization to the end of the treatment at 14 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sultanah Bahiyah Hospital, Alor Setar
Alor Star, Kedah, Malaysia · Recruiting
Hospital Pulau Pinang
George Town, Pulau Pinang, Malaysia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.